Opinion|Videos|November 18, 2024
Real-World Clinical Experience With JAK Inhibitors
Key Takeaways
- JAK inhibitors offer a novel approach for alopecia treatment, with varying outcomes and tolerability among different agents observed by clinicians.
- Systemic JAK inhibitors provide advantages over traditional therapies, including targeted action and potential efficacy in severe alopecia cases.
Panelists discuss their clinical experiences with Janus kinase (JAK) inhibitors for treating alopecia, noting observed differences in outcomes and tolerability among various systemic JAK inhibitors, while highlighting the advantages of these therapies over traditional local and systemic treatment options.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What has been your clinical experience with JAK inhibitors for treatment of alopecia?
a. Have you observed differences in outcomes and/or tolerability with using different systemic JAK inhibitors?
What are the advantages of using systemic JAK inhibitor therapies compared with traditional local or systemic therapies?
Advertisement
Related to this article
The FDA updated the risankizumab label to make pretreatment TB evaluation a matter of clinical judgment across all indications, including psoriasis.
Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.
Final VALUE data show fewer drug changes with risankizumab vs other biologics over 37 months in patients with psoriasis and comorbid psoriatic arthritis.
Stay updated with the latest healthcare breakthroughs, including new TRANSCEND-T2D-2 data and FDA actions.
The plasmid DNA immunotherapy Voceryq gained FDA accelerated approval after 27% of RRP-001 patients needed no surgery for 12 months.
IgAN late-breakers led the meeting, alongside new data on aspirin, dialysis access, donor pregnancy, potassium, and depression.
Experts discuss remibrutinib, the first FDA-approved therapy for symptomatic dermographism: RemIND data, bleeding counseling, and where it fits in practice
Five liver societies define ACLF as liver failure plus extrahepatic organ dysfunction or failure, with three grades and FDA-informed trial endpoints.
Advertisement
Advertisement
Trending on HCPLive
1
Cardiac Health Indicators Improve Following CCM Implantation in Heart Failure
2
Sarcoidosis Care Starts With Inflammation vs Fibrosis: Rohit Gupta, MD
3
ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know
4
HCPLive Five at CHEST 2026
5